Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase III Randomized Trial of Eribulin (NSC #707389) With Gemcitabine Versus Standard of Care (Physician's Choice) for Treatment of Metastatic Urothelial Carcinoma Refractory to, or Ineligible for, Anti PD1/PDL1 Therapy

NCT04579224 is registered in ClinicalTrials.gov with National Cancer Institute (NCI) as lead sponsor.

NCT NCT04579224
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04579224 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase III Randomized Trial of Eribulin (NSC #707389) With Gemcitabine Versus Standard of Care (Physician's Choice) for Treatment of Metastatic Urothelial Carcinoma Refractory to, or Ineligible for, Anti PD1/PDL1 Therapy
Lead sponsor
National Cancer Institute (NCI)
Phase
Phase 3
Overall status
Active, not recruiting
Start date
June 28, 2021
Completion date
August 15, 2030
Enrollment
184 (estimated)
Sites
448

Conditions

As the registry lists them; a condition with its own page is linked.

metastatic bladder urothelial carcinoma, metastatic urothelial carcinoma, refractory bladder urothelial carcinoma, refractory urothelial carcinoma, stage iv bladder cancer ajcc v8